BHVN
Price
$11.36
Change
-$0.14 (-1.22%)
Updated
Feb 13 closing price
Capitalization
1.51B
33 days until earnings call
Intraday BUY SELL Signals
CDXS
Price
$1.20
Change
+$0.02 (+1.69%)
Updated
Feb 13 closing price
Capitalization
108.39M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHVN vs CDXS

Header iconBHVN vs CDXS Comparison
Open Charts BHVN vs CDXSBanner chart's image
Biohaven
Price$11.36
Change-$0.14 (-1.22%)
Volume$2.09M
Capitalization1.51B
Codexis
Price$1.20
Change+$0.02 (+1.69%)
Volume$1.38M
Capitalization108.39M
BHVN vs CDXS Comparison Chart in %
BHVN
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BHVN vs. CDXS commentary
Feb 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 15, 2026
Stock price -- (BHVN: $11.36 vs. CDXS: $1.20)
Brand notoriety: BHVN and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 69% vs. CDXS: 127%
Market capitalization -- BHVN: $1.51B vs. CDXS: $108.39M
BHVN [@Biotechnology] is valued at $1.51B. CDXS’s [@Biotechnology] market capitalization is $108.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $124.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 1 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 1 green, 4 red.
According to our system of comparison, BHVN is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 4 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • BHVN’s TA Score: 4 bullish, 5 bearish.
  • CDXS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BHVN is a better buy in the short-term than CDXS.

Price Growth

BHVN (@Biotechnology) experienced а -2.07% price change this week, while CDXS (@Biotechnology) price change was -9.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.41%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +22.89%.

Reported Earning Dates

BHVN is expected to report earnings on Mar 19, 2026.

CDXS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+2.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($1.51B) has a higher market cap than CDXS($108M). BHVN YTD gains are higher at: 0.620 vs. CDXS (-26.380). CDXS has higher annual earnings (EBITDA): -55.32M vs. BHVN (-782.76M). BHVN has more cash in the bank: 260M vs. CDXS (58.7M). CDXS has less debt than BHVN: CDXS (68.6M) vs BHVN (314M). CDXS has higher revenues than BHVN: CDXS (52.9M) vs BHVN (0).
BHVNCDXSBHVN / CDXS
Capitalization1.51B108M1,395%
EBITDA-782.76M-55.32M1,415%
Gain YTD0.620-26.380-2%
P/E RatioN/AN/A-
Revenue052.9M-
Total Cash260M58.7M443%
Total Debt314M68.6M458%
FUNDAMENTALS RATINGS
BHVN vs CDXS: Fundamental Ratings
BHVN
CDXS
OUTLOOK RATING
1..100
6254
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6093
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (27) in the Chemicals Specialty industry is in the same range as BHVN (43) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to BHVN’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to BHVN’s over the last 12 months.

CDXS's SMR Rating (99) in the Chemicals Specialty industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to BHVN’s over the last 12 months.

BHVN's Price Growth Rating (60) in the Pharmaceuticals Major industry is somewhat better than the same rating for CDXS (93) in the Chemicals Specialty industry. This means that BHVN’s stock grew somewhat faster than CDXS’s over the last 12 months.

BHVN's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that BHVN’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNCDXS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SNWIX77.681.28
+1.68%
Easterly Snow Small Cap Value I
CCTRX13.620.17
+1.26%
Columbia Sm Cp Val and Inflection R
JCMVX30.040.21
+0.70%
JPMorgan Mid Cap Value C
DESUX25.880.04
+0.15%
DWS Enhanced Core Equity R6
DWGHX15.33-0.02
-0.13%
American Funds Dvlpg Wld Gr&Inc F2

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with CDXS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then CDXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
-1.22%
CDXS - BHVN
57%
Loosely correlated
+1.69%
OCUL - BHVN
56%
Loosely correlated
-1.99%
TPST - BHVN
56%
Loosely correlated
+2.16%
AGIO - BHVN
55%
Loosely correlated
-0.39%
NTLA - BHVN
55%
Loosely correlated
+2.15%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been closely correlated with ARTV. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDXS jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.69%
ARTV - CDXS
70%
Closely correlated
+0.25%
VTGN - CDXS
68%
Closely correlated
-7.23%
LENZ - CDXS
68%
Closely correlated
-0.69%
BCAB - CDXS
67%
Closely correlated
-8.93%
ARCT - CDXS
67%
Closely correlated
+0.56%
More